



An Outline of Implantable Cardioverter Defibrillators (ICDS) and its Employments

John Moses*

Department of Medicine, Temple University, USA

INTRODUCTION

Discrimination algorithms have improved, allowing ICDs to better differentiate between harmless arrhythmias and life-threatening ventricular tachycardias or fibrillations. ICD implantation carries a risk of infection, particularly in the weeks following the procedure. Rare complications, such as lead dislodgement, malfunction, or fracture, can necessitate additional procedures. Shocks delivered by ICDs, especially high-energy shocks, can be uncomfortable or even painful for patients. Living with an ICD can have psychological and emotional implications for patients, including anxiety related to the anticipation of shock therapy. Many modern ICDs are equipped with remote monitoring capabilities. Healthcare providers can track the device's functionality and the patient's heart rhythm data remotely, allowing for timely adjustments and interventions. Some ICDs are equipped with multiple leads that can sense and treat arrhythmias originating in different chambers of the heart. This precise therapy delivery enhances treatment efficacy. . Access to ICD therapy may be limited in some regions or healthcare systems. Some patients may struggle to come to terms with the need for an ICD. Accepting the presence of a device that constantly monitors and can deliver shocks can be emotionally challenging. The decision to implant an ICD is not made lightly and involves a careful consideration of the individual patient's medical history, risk factors, lifestyle, and preferences [1,2].

DESCRIPTION

For some patients, the benefits far outweigh the potential drawbacks, especially if they have a significant risk of life-threatening arrhythmias. Others may need to weigh the pros and cons more carefully, considering factors such as their tolerance for shock therapy and the potential impact on their mental and emotional well-being. Healthcare providers play a crucial role in guiding patients through this decision-making process. They must thoroughly educate patients about the benefits and potential disadvantages of ICD therapy, address-

ing concerns and ensuring that patients make informed choices aligned with their values and goals. ICDs can be programmed to deliver different levels of therapy based on the specific needs of each patient. For individuals at risk of sudden cardiac death, ICDs provide reassurance and peace of mind, enabling them to lead more active lives without the constant fear of an arrhythmic event. Traditional ICDs are implanted within the heart and blood vessels. Subcutaneous ICDs, however, are positioned just beneath the skin, eliminating the need for intravascular leads. This design reduces the risk of lead-related complications. Some ICDs are equipped with multiple leads that can sense and treat arrhythmias originating in different chambers of the heart, allowing for more precise therapy delivery. Many modern ICDs are equipped with remote monitoring capabilities, allowing healthcare providers to track the device's functionality and the patient's heart rhythm data remotely [3,4].

CONCLUSION

Traditional ICDs can pose challenges during Magnetic Resonance Imaging (MRI) procedures due to the metal components. MRI-compatible ICDs have been developed to address this limitation. ICD implantation carries a risk of infection, especially in the initial weeks following the procedure. Rare complications, such as lead dislodgement, malfunction, or fracture, may necessitate further interventions. ICDs can deliver shocks that are uncomfortable or painful. Patients should be educated about the possibility of shock therapy and its sensations. ICD batteries have a limited lifespan, typically around 5 to 10 years, after which the device requires replacement.

ACKNOWLEDGEMENT

None.

CONFLICT OF INTEREST

The author's declared that they have no conflict of interest.

Received:	01-August-2023	Manuscript No:	IPIC-23-18065
Editor assigned:	03-August-2023	PreQC No:	IPIC-23-18065 (PQ)
Reviewed:	17-August-2023	QC No:	IPIC-23-18065
Revised:	22-August-2023	Manuscript No:	IPIC-23-18065 (R)
Published:	29-August-2023	DOI:	10.21767/2471-8157.9.8.72

Corresponding author John Moses, Department of Medicine, Temple University, USA, E-mail: johnmoses@tuhs.temple.edu

Citation Moses J (2023) An Outline of Implantable Cardioverter Defibrillators (ICDS) and its Employments. Interv Cardiol J. 9:72.

Copyright © 2023 Moses J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES

1. Tan JL, Russo AM (2022) The subcutaneous implantable cardioverter-defibrillator should be considered for all patients with an implantable cardioverter-defibrillator indication. *Heart Rhythm* 02 3(5):589-596.
2. Kamp NJ, Al-Khatib SM (2019) The subcutaneous implantable cardioverter-defibrillator in review. *Am Heart J* 217:131-139.
3. Adduci C, Palano F, Silvetti G, Cosentino P, Francia P (2020) Prevention of sudden cardiac death: Focus on the subcutaneous implantable cardioverter-defibrillator. *High Blood Press Cardiovasc Prev* 27(4):291-297.
4. Waldmann V, Marquie C, Bessiere F, Perrot D, Anselme F, et al. (2023) Subcutaneous implantable cardioverter-defibrillators in patients with congenital heart disease. *J Am Coll Cardiol* 82(7):590-599.